Catalyst Pharmaceuticals, Inc. P/E Ratio 2002–2025
Catalyst Pharmaceuticals, Inc. reported 13.89 of price-to-earnings ratio for fiscal 2025. That was 12.8% lower than fiscal 2024. Compared with fiscal 2020, the change was +195.3%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 13.89 | -12.8% |
| FY 2024 | 15.93 | -40.3% |
| FY 2023 | 26.68 | +7.6% |
| FY 2022 | 24.80 | +35.5% |
| FY 2021 | 18.30 | +289.0% |
| FY 2020 | 4.70 | -62.4% |
| FY 2019 | 12.50 | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
| FY 2010 | — | — |
| FY 2009 | — | — |
| FY 2008 | — | — |
| FY 2007 | — | — |
| FY 2006 | — | — |
| FY 2005 | — | — |
| FY 2004 | — | — |
| FY 2003 | — | — |
| FY 2002 | — | — |
Source: Catalyst Pharmaceuticals, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open CPRX 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Catalyst Pharmaceuticals, Inc. reported 13.89 of price-to-earnings ratio for fiscal 2025. That was 12.8% lower than fiscal 2024. Compared with fiscal 2020, the change was +195.3%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Catalyst Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeCatalyst Pharmaceuticals, Inc. — frequently asked questions
What is Catalyst Pharmaceuticals, Inc.'s price-to-earnings ratio?
Catalyst Pharmaceuticals, Inc. (CPRX) reported price-to-earnings ratio of 13.89 for fiscal year 2025, per its SEC filings.
How has Catalyst Pharmaceuticals, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2002 and 2025, CPRX's price-to-earnings ratio grew at roughly 0.5% per year (compound annual rate), from 12.50 to 13.89.
Where does this data come from?
Figures are computed from Catalyst Pharmaceuticals, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More CPRX financial history
Full CPRX fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →